Cullinan Therapeutics, Inc. (CGEM) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 8 Buy.
The consensus price target is $30.43 (low: $26.00, high: $38.00), representing an upside of 112.1% from the current price $14.35.
Analysts estimate Earnings Per Share (EPS) of $-2.99 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.11 vs est $-2.99 (missed -4%). 2025: actual $-3.72 vs est $-3.56 (missed -4.4%). Analyst accuracy: 96%.
CGEM Stock — 12-Month Price Forecast
$30.43
▲ +112.06% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Cullinan Therapeutics, Inc., the average price target is $30.43, with a high forecast of $38.00, and a low forecast of $26.00.
The average price target represents a +112.06% change from the last price of $14.35.
Highest Price Target
$38.00
Average Price Target
$30.43
Lowest Price Target
$26.00
CGEM Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to Cullinan Therapeutics, Inc. in the past 3 months
EPS Estimates — CGEM
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.11
vs Est –$2.99
▼ 3.9% off
2025
Actual –$3.72
vs Est –$3.56
▼ 4.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — CGEM
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
